SCHEMBL12366341

SCHEMBL12366341

Cc1ccc(C2=CCOc3ccc(C(=O)N=C(N)N)cc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC9A1 P19634 4/20 0.41
▸ HTR2B P41595 8/20 0.40
▸ HTR7 P34969 7/20 0.40
▸ DRD2 P14416 1/20 0.38
▸ ADRA1D P25100 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ ADRA1B P35368 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ RARA P10276 1/20 0.36
▸ RARB P10826 1/20 0.36
▸ RARG P13631 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12366388 0.89 HTR2B (0.40) SLC9A1HTR2BHTR7DRD2ADRA1D
SCHEMBL2259569 0.88 SLC9A1 (0.41) SLC9A1HTR2BHTR7DRD2ADRA1D
SCHEMBL12366354 0.88 HTR2B (0.44) SLC9A1HTR2BHTR7DRD2ADRA1D
SCHEMBL12366373 0.88 HTR2B (0.45) SLC9A1HTR2BHTR7DRD2ADRA1D
SCHEMBL12366329 0.88 HTR2B (0.47) SLC9A1HTR2BHTR7DRD2ADRA1D
SCHEMBL12366383 0.88 SLC9A1 (0.46) SLC9A1HTR2BHTR7DRD2ADRA1D
SCHEMBL12366355 0.88 NPC1 (0.41) SLC9A1HTR2BHTR7DRD2ADRA1D
SCHEMBL12366470 0.86 HTR7 (0.41) SLC9A1HTR2BHTR7DRD2ADRA1D
SCHEMBL12366416 0.86 SLC9A1 (0.47) SLC9A1HTR2BHTR7DRD2ADRA1D
SCHEMBL12366371 0.85 SLC9A1 (0.42) SLC9A1HTR2BHTR7DRD2ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2011-08-25 — — US disclosed
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2011-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E SLC9A1 1693/4885HTR2B 7/4885HTR7 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback